Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer

Jia Nan Chen, Zheng Liu, Zhi Jie Wang, Shi Wen Mei, Hai Yu Shen, Juan Li, Wei Pei, Zheng Wang, Xi Shan Wang, Jun Yu, Qian Liu

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND Lateral lymph node metastasis is one of the leading causes of local recurrence in patients with advanced mid or low rectal cancer. Neoadjuvant chemoradiotherapy (NCRT) can effectively reduce the postoperative recurrence rate; thus, NCRT with total mesorectal excision (TME) is the most widely accepted standard of care for rectal cancer. The addition of lateral lymph node dissection (LLND) after NCRT remains a controversial topic. AIM To investigate the surgical outcomes of TME plus LLND, and the possible risk factors for lateral lymph node metastasis after NCRT. METHODS This retrospective study reviewed 89 consecutive patients with clinical stage II-III mid or low rectal cancer who underwent TME and LLND from June 2016 to October 2018. In the NCRT group, TME plus LLND was performed in patients with short axis (SA) of the lateral lymph node greater than 5 mm. In the non-NCRT group, TME plus LLND was performed in patients with SA of the lateral lymph node greater than 10 mm. Data regarding patient demographics, clinical workup, surgical procedure, complications, and outcomes were collected. Multivariate logistic regression analysis was performed to evaluate the possible risk factors for lateral lymph node metastasis in NCRT patients. RESULTS LLN metastasis was pathologically confirmed in 35 patients (39.3%): 26 (41.3%) in the NCRT group and 9 (34.6%) in the non-NCRT group. The most common site of metastasis was around the obturator nerve (21/35) followed by the internal iliac artery region (12/35). In the NCRT patients, 46% of patients with SA of LLN greater than 7 mm were positive. The postoperative 30-d mortality rate was 0%. Two (2.2%) patients suffered from lateral local recurrence in the 2-year follow up. Multivariate analysis showed that cT4 stage (odds ratio [OR] = 5.124, 95% confidence interval [CI]: 1.419-18.508; P = 0.013), poor differentiation type (OR = 4.014, 95%CI: 1.038-15.520; P = 0.044), and SA ≥ 7 mm (OR = 7.539, 95%CI: 1.487-38.214; P = 0.015) were statistically significant risk factors associated with LLN metastasis. CONCLUSION NCRT is not sufficient as a stand-alone therapy to eradicate LLN metastasis in lower rectal cancer patients and surgeons should consider performing selective LLND in patients with greater LLN SA diameter, poorer histological differentiation, or advanced T stage. Selective LLND for NCRT patients can have a favorable oncological outcome.

Original languageEnglish (US)
Pages (from-to)2877-2888
Number of pages12
JournalWorld Journal of Gastroenterology
Volume26
Issue number21
DOIs
StatePublished - Jun 7 2020

Keywords

  • Lateral lymph node dissection
  • Locoregional recurrence
  • Lymphatic metastasis
  • Neoadjuvant therapies
  • Rectal neoplasms
  • Total mesorectal excision

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer'. Together they form a unique fingerprint.

Cite this